echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Green leaf pharmaceutical update: Class 1 new drugs to complete Phase I clinical research

    Green leaf pharmaceutical update: Class 1 new drugs to complete Phase I clinical research

    • Last Update: 2021-01-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    The LY03012 declaration of astronomy is the treatment of chronic pain such as peripheral nerve pain, fibromyalgia and osteoarthritis.
    The Phase I study, using randomized, double-blind, placebo-controlled, single and multiple dose increments, was designed to assess the safety, toerability and PK characteristics of healthy subjects after taking LY030112, 60 subjects participated in a single drug study (phase I), 48 subjects entered one daily and took multiple drug studies for 7 consecutive days (phase II).
    results showed that healthy subjects took 80 to 400 mg a day for 80 to 320 mg for 7 days after the overall safety, tolerance is good, the common adverse events are mainly nausea, vomiting, drowsiness and so on.
    adverse events were mostly mild, a small number were moderate, all had good prognosmation, no subjects withdrew from the study due to adverse events, and no unannored adverse events occurred.
    Excessive sedation and drowsiness has always been a defect in chronic pain treatment, seriously affecting work and life, such as driving, mechanical operation, and most social activities, including communication, but also lead to the dose of medication can not be further improved, so can not achieve better results, is the current clinical treatment of chronic pain is an important reason for the lack of effectiveness.
    IQIVA data, analgesants reached 15.82 billion yuan in China in 2019, rising at a compound annual growth rate of 17.4% from 2017 to 2019.
    analgesics such as buprenorphine patches and fentanyl patches from the Greenleafe Group are now available worldwide.
    addition, a class 1 new drug LPM3480392 injection (LY03014) and other innovative analgesics are in the research stage.
    content Source: Medical Rubik's Cube Info
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.